Real-world COVID-19 vaccine effectiveness

Victoria Kirsh, MSc, PhD
Scientific Associate, Ontario Health Study
Assistant Professor, Dalla Lana School of Public Health,
University of Toronto

CanPath
Canadian Partnership
for Tomorrow's Health

Partenariat canadien
pour la santé de demain

Disclaimer

I have no conflicts of interest to
declare related to this study.

CanPath

Background

- Weak or waning humoral response in tandem with the emergence of new viral variants, capable of potentially escaping immune response, lead to a continued risk of SARS-CoV-2 infection.

- Omicron is currently the dominant variant circulating globally.

- Prior vaccination:
  ‣ Effective against severe COVID-19 and hospitalization due to Omicron variants
  ‣ Less effective against asymptomatic and symptomatic, mild breakthrough infections.

CanPath

Objective

To measure vaccine effectiveness in a real-world setting over the course of the pandemic.

Our aim is to untangle the relationship between vaccination status (how many doses, of which brands, and elapsed time following each dose) and risk of new COVID-19 infections, while controlling for base infection rates that may vary over the follow-up and by geographic region; as well as participant demographics, and adherence with public health recommendations.

CanPath

Study population: 22,300 CanPath participants

Atlantic PATH
3,322

BC Generations Project
3,869

CARTaGENE (Quebec)
4,500

Alberta's Tomorrow Project
n/a

Saskatchewan PATH
n/a

Manitoba Tomorrow Project
667

Ontario Health Study
9,942

CanPath

Dried blood spots collected at up to 3 time points

- Study population
  - Aged ≥ 19 years, 66% female
  - Completed questionnaires and provided dried blood spots using mailed kits at up to 3 time points during the vaccine rollout

CanPath

Comprehensive study questionnaire

Vaccination status (brand and date received)

COVID-19 test results and dates / suspected infection and dates

Symptoms experienced (if any)

Care/hospital related information

Comorbidities, smoking status, BMI, influenza vaccination

Preventive measures taken

Potential source and date of exposure

Job classifications for front-line workers

Impact of the pandemic on mental, emotional, social and financial wellbeing

COVID-19 long-term effects

CanPath

Anti-N IgG serology results capture unconfirmed infections

- Measured three antibody levels:
  - ▸ Anti-spike (SmT1) IgG : marker of vaccination
  - ▸ Anti-receptor binding domain (RBD) IgG : marker of vaccination
  - ▸ Anti-nucleocapsid (N) IgG: marker of vaccination or natural infection

- Used anti-N IgG serology results to capture asymptomatic and unconfirmed infections
  - ▸ Two distinct thresholds for N were set to reduce false negatives:
    - at low seroprevalence (timepoint 1) , specificity=0.995, sensitivity=0.998
    - at higher seroprevalence (timepoints 2 and 3), specificity=0.904, sensitivity=0.876
  - ▸ Adequately assigned participants to the respective groups

- Determined whether anti-SmT1 and anti-RBD antibody levels are associated with risk of infection

CanPath

More than half of COVID-19 diagnoses were among those who neither knew nor suspected they were infected

Source of COVID-19 diagnosis

Antibody/Rapid 18%

Antibody/PCR 11%

PCR 6%

Rapid test 3%

Antibody only 62%

14% suspected

86% did not suspect

CanPath

Model includes time-varying vaccine-related variables

- Time-varying exposures
  - Vaccination number (0-6)
  - Vaccine brand most recently received (Moderna, Pfizer, AstraZeneca, other)
  - Bivalent vaccine (yes, no)
    - Assumptions were based on Health Canada's approval dates of:
      1 Sep 2022 for the new bivalent Moderna vaccine and
      7 Oct 2022 for the new bivalent Pfizer vaccine

- Covariates
  - Age, sex, ethnicity, geographic region (cohort)
  - Cancer history, immunocompromised status, body mass index
  - Essential worker status
  - Preventive measures: travel, mask use, use of public transportation, avoidance of indoor gatherings

CanPath

Main outcome is time to first SARS-CoV-2 infection

- Time to the first SARS-CoV-2-positive test during 2 periods:
  - ▸ Omicron period (2 Dec 2021 to Jan 2023)
  - ▸ Pre-Omicron period (11 Jan 2020 to 1 Dec 2021)
  - ▸ Participants were no longer at risk after their first positive test
  - ▸ Noninfected participants were censored at the time of the last available follow-up questionnaire

- Cases included irrespective of symptoms or severity (n=2533)

- Excluded those anti-N IgG positive with unknown infection dates (n=2099)

- Vaccine effectiveness (VE) = (1- hazard ratio (HR)) x100%

Symptoms caused by Omicron

CanPath

VE robust pre-Omicron

- Evidence of robust immunity:
 - After an initial delay to vaccine effectiveness taking effect

VE against Omicron infections waning

- Evidence of waning immunity after being fully vaccinated or boosted:
  - from a high of 56-68% at one or two months
  - to a low of 3-30% at five months or longer

CanPath

Highest VE among Moderna recipients; boosting with a bivalent vaccine has similar effect as boosting with monovalent

Omicron-predominant period

An increase in predicted anti-SmT1 and anti-RBD antibody levels is associated with a decreased risk of infection

Omicron-predominant period

HR
(per 1 SD increase in antibody level)

CanPath

Learnings/challenges

- Time since vaccination by dose number and calendar time are inextricably confounded: two years into the pandemic, infection rates increased dramatically
  - Stratified analyses by pre-Omicron and Omicron predominant periods

- Access to PCR testing varied over time
  - Incorporated baseline serology results
  - Adapted questionnaires to capture use of at-home rapid antigen tests

- Must take measures to avoid misclassification of non-cases as cases

CanPath

Conclusions

- Our results indicate the short-term effectiveness of full or booster vaccination in preventing SARS-CoV-2 Omicron infection.

- Booster campaigns could be strategically used to rapidly boost population immunity before upcoming waves of infections.

Study Team

Co-Investigators
Philip Awadalla
Kimberly Skead

Key Collaborators
Anne-Claude Gingras
Karen Colwill & team
John Matelski

National Coordinating Centre
John McLaughlin
Tedd Konya
Nouar Elkhair
Jasvinei Sritharan
Treena McDonald
Megan Fleming
Sheraz Cheema

Ontario Health Study Team
Kelly McDonald
Michael Abramov
Rachel Chepesiuk
Kathleen Dowell
Lindsay Hayman
Polina Kargapolova
Nazanin Khobzi
Igor Koganov
Ayush Lall
Mason LeVon
Alexis Mantell
Zahra Moazami
Helen Qu
Vali Radoi
Sarah Salih
Charles Zhu

CanPath

Thank you to the sponsors and hosts of CanPath's antibody study and to the participants across the regional cohorts who generously donated their time, information and biological samples.

CanPath

CanPath.ca

CanPath

Canadian Partnership
for Tomorrow's Health

Partenariat canadien
pour la santé de demain